header logo image


Page 192«..1020..191192193194..200210..»

Inspiring innovation | UDaily – UDaily

February 17th, 2021 1:54 am

Article by Karen B. Roberts Photo illustration by David Barczak February 15, 2021

According to Hungarian biochemist Albert Szent-Gyrgyi, who won the Nobel Prize in physiology or medicine in 1937 for his study of vitamin c and cell respiration, Innovation is seeing what everybody has seen and thinking what nobody has thought.

Most of the time, innovators do not know if their ideas will pan out. A lot of the time they dont. When failure occurs, inventors step back, reconsider and regroup, then keep pursuing their ideas, incorporating lessons learned along the way in order to pivot or start anew.

As we celebrate National Innovation Day on Tuesday, Feb. 16, UDaily asked several University of Delaware researchers who are fellows of the National Academy of Inventors to share their successes, stumbling blocks and suggestions on what it takes to innovate, invent and inspire new solutions to challenges facing society and the world.

Eleftherios (Terry) Papoutsakis is the Unidel Eugene Du Pont Chair ofChemical and Biomolecular Engineering. He was selected for NAI fellow status in December 2020 for translational biotechnology contributions that have profoundly impacted sustainable manufacturing and human health. One technology that Papoutsakis said has proven particularly useful and successful is his teams development of a method to engineer microparticles that deliver gene-regulating material to hematopoietic stem and progenitor cells that live deep in our bone marrow, where they direct the formation of blood cells. The technology could be useful in treatment for inherited blood disorders, such as sickle cell anemia, or to improve personalized medicine. The discovery, he said, was completely unexpected, but it is currently generating a lot of interest from companies.

Q: Were there inventors that you looked up to as a kid or other people or events that inspired your inventiveness?

Papoutsakis: As a child, I did not know what inventors do but I was amazed by the ability of airplanes to fly, thediscovery of plastics, fertilizers and pesticides (my dad hadan orchard and could tell how important they were) and theconcept of the vaccine. Mygeneration first experienced the benefits of the polio vaccine andvaccines for otherdevastatingdiseases. That iswhy I decided tobecome achemical engineer. I did not know at the time how broad thefield was, but I had a cousin-in-law who wasforward-looking, and he explained to me the potential of thefield and its breadth.

Q: What are some of the stumbling blocks youve encountered as an inventor? How did you overcome them?

Papoutsakis: Two things come to mind. First, I wish I had taken a course inpatent law and patent writing. I amstill learning as I go along; however, I cant help but think about what might have been different if Id had training. I missed several opportunities to protect my researchwork.

Second, Iwish I understood better how tosell (commercialize) myinventions and be good at it. It takes the right personality and athick skin to swallowwithoutpain therejections (and I lack both), plus a lot of time to keeppushing.

Q: Are the best innovators also subject-matter experts? Or do great innovations just as often or more often flow from an idea from someone who does not know how to bring that idea to life, but gets connected with someone who does?

Papoutsakis: Not necessarily, intuition and imagination are more important, I think. In terms of which is better, subject-matter expertise or connections, I think the latter is as potent anavenue as the subject-matter expertwho has intuition and imagination, orthe rightpeople towork with.

Q: What are the critical innovations we need now?

Papoutsakis: We havedone wellwith theeasy thingsthat make a lot of money like social media and the Googles and the Amazons of the world. We needthese things, and the folks that developed them aregeniuses. But we still need tosolvereallybig problems inenergy, the environment, global warming, sustainablemanufacturing and transportation. Then there is the problem of affordable and adaptable health care. The pandemic is just a reminder and anadvance notice asto whathumanity might beup against as wemoveforward.

Q: Are there ways to develop/nurture an innovative mind and keep that spark alive?

Papoutsakis: Patents are a key part of invention. I think it is important to engage both undergrads and graduate students in all aspects of the patent process early on. From patent applications to writing provisional patents and, later, work with lawyers to file the utility patents or even just to read them. It is so different from reading scientific papers. Having this knowledge and background early in ones academic or industrial career would be beneficial for an individual and for future inventors working with that individual to keep the spark alive.

Q: Is there anything you would tell your younger inventor self if you could?

Papoutsakis: At the risk of repeating myself, I would tell my younger self to take a course in patent writing and entrepreneurship, to work with a master in my field and tothink outside of the box. The best ideas are not necessarily based on expensive science.

Kristi Kiick, Blue and Gold Distinguished Professor of Materials Science and Engineering, was named a fellow of the National Academy of Inventors in 2019. Her research involves developing biomaterials to advance medicine, from healing wounds faster and improving chemotherapies, to treating heart and musculoskeletal diseases.Kiicks proudest moment of invention occurred as a graduate student at the California Institute of Technology when she discovered that the natural protein-synthesis machinery of E. coli can be tuned to use novel chemical groups not normally used by nature in protein synthesis. Specific enzymes that normally control what amino acids are included in proteins can simply be produced at higher levels in the bacterial cell. This change alone can permit an enormous range of chemically reactive proteins to be produced. Other scientists have built on Kiicks original approach to create applications that now help scientists learn about processes inside of cells in order to better understand development, disease and drug treatments.

Q: Were there inventors that you looked up to as a kid or other people or events that inspired your inventiveness?

Kiick: My exposure to and interest in invention occurred while I was a research scientist at Kimberly Clark Corporation. I was inspired by many of my co-workers, who each approached innovation and invention differently.Some people saw research articles and applied those findings to technical advances we were trying to make in our laboratories, and others found inspiration from the fundamental principles of the world around them.It was inspiring and a little bit intimidating for me to watch how these colleagues generated and implemented ideas.It definitely changed how I looked at science and its application in solving technical challenges.

Q: What are some of the stumbling blocks youve encountered as an inventor? How did you overcome them?

Kiick: Honestly, the biggest stumbling block for me was trusting my scientific intuition as a young scientist.It took me a long time to understand that my ideas could be novel and that what might appear as an experimental failure could actually be a new discovery.The thoughtful and supportive mentoring by my graduate adviser was pivotal in my making this transition.

Q: Are the best innovators also subject-matter experts? Or do great innovations just as often or more often flow from an idea from someone who does not know how to bring that idea to life, but gets connected with someone who does?

Kiick: The best innovations dont necessarily come from subject matter experts. Having a fresh look at a question or an idea can spark innovation. The implementation of many technical innovations is often best accomplished by a diverse team, where deep technical knowledge can be applied in a new way because someone has thought to look at the idea differently.

Q: What are the critical innovations we need now?

Kiick: I think there are still critical innovations to be made in how we apply massive amounts of data to create new technologies and social systems that allow us to be good stewards of our planet, our communities and ourselves.

Q: Are there ways to develop/nurture an innovative mind and keep that spark alive?

Kiick: As Walt Whitman said, Be curious, not judgmental.

Q: Is there anything you would tell your younger inventor self if you could?

Kiick: I just laughed out loud.I would say surround yourself with supportive people who are trying to make a positive difference. Say yes, and and not no, but. Travel more.Enjoy the journey.

Yushan Yan, Henry B. du Pont Chair in Chemical and Biomolecular Engineering, was named a fellow of the National Academy of Inventors in 2018. He is a co-inventor on more than 20 patents. Among his teams most recent inventions is a new class of ionically conducting polymers that have the potential to drastically reduce the cost of green hydrogen and fuel cells and to help deeply decarbonize all sectors of our economy. In 2019, Yan launched a startup called W7energy, now known as Versogen, alongside UD students and alumni to commercialize this new class of polymers and membranes. Hes proud to report that the company has grown rapidly over the last two years.

Q: Were there inventors that you looked up to as a kid or other people or events that inspired your inventiveness?

Yan: When I was a kid, I did not understand the concept of invention, per se, but I did like tinkering with my hands. For example, I enjoyed making my own primitive telescope or modifying my kerosene lamp to make it burn cleaner. Years later I would learn that what I did to the lamp was to turn the diffusion flame (where the fuel and oxidizer are separate prior to the reaction) into a premixed flame (where the fuel and oxidizer are mixed) like those found in a Bunsen burner.

Q: What are some of the stumbling blocks youve encountered as an inventor? How did you overcome them?

Yan: Coming up with an invention that is useful is not difficult, but developing a good sense of what kind of invention can be commercialized and have a measurable societal impact took some time.

Q: What are the critical innovations we need now?

Yan: As a society we still need many critical innovations in all kinds of fields. For myself, being able to reduce the cost of hydrogen and fuel cells to help deeply decarbonize our economy is a very high priority.

Q: Are there ways to develop/nurture an innovative mind and keep that spark alive?

Yan: I think it is important to instill curiosity into our children and to convince them that everyone has the potential to change what is possible.

See original here:
Inspiring innovation | UDaily - UDaily

Read More...

G-CON PODs Successfully Delivered for Cell Therapy Manufacturing on an Accelerated Timeline – PRNewswire

February 17th, 2021 1:54 am

"This project was a testament to the fact that rigorous planning and project execution lead to better results."

The advanced coordination between the facility and PODs reduced overlap and allowed for a predictable timeline and budget. Moreover, the client's having a single point of contact eliminated the risk of scope gaps that often lead to delay and increased project cost.

About G-CON Manufacturing

G-CON Manufacturing designs, builds and installs prefabricated G-CON POD cleanrooms. G-CON's POD portfolio provides cleanrooms in several dimensions for a variety of uses, from laboratory environments to personalized medicine and production process platforms. G-CON POD cleanroom units surpass traditional cleanroom structures in scalability, mobility and the possibility of repurposing the PODs once the production process reaches its lifecycle end. For more information, please visit G-CON's website athttp://www.gconbio.com.

About G-CON Building Services

G-CON Building Services simplifies pharmaceutical and biopharmaceutical cleanroom projects by providing effective turnkey host facility project management that leads to cost-efficient and on time results.

SOURCE G-CON Manufacturing

http://www.gconbio.com/

Read more here:
G-CON PODs Successfully Delivered for Cell Therapy Manufacturing on an Accelerated Timeline - PRNewswire

Read More...

Pharma Clinical Trial Digitization Market 2021 Rising Demand and Grow Opportunities Antidote Technologies, Aparito, Clinerion, CliniOps, Inc., KSU |…

February 17th, 2021 1:54 am

Clinical trial digitization allows the processing in different forms of voluminous patient-related data. Such data are being used by pharmaceutical companies to improve the effectiveness of trial execution.

Growing demand for quality data is expected to drive the market growth. Some of the other factors such as increasing demand for personalized drugs, increasing adoption of new technology in clinical research, growing research & development promoting outsourcing and increasing diseases prevalence will drive the market in the forecast period of 2020 to 2027

Competitive Landscape and Pharma Clinical Trial Digitization Market Share Analysis

Pharma clinical trial digitization market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to pharma clinical trial digitization market.

Pharma Clinical Trial Digitization Market Scope

The pharma clinical trial digitization market is segmented on the basis of countries into U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of pharma clinical trial digitization market is further analyzed based on maximum granularity into further segmentation. On the basis of services, the pharma clinical trial digitization market is segmented into drug dose adjustment, drug impact monitoring, medical prescription system, bioprinting, preventive therapy, and individualized drug printing. Based on application, the market is segmented into clinical data management, trial monitoring, patient recruitment and enrollment. The pharma clinical trial digitization market on the basis of theme is segmented into digital continuity acrossclinical trial IT systems, patient-centric remote and virtual trial design and direct-to-patient home services.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pharma-clinical-trial-digitization-market&pm

Key Pointers Covered in the Pharma Clinical Trial Digitization Market Industry Trends and Forecast to 2027

Pharma Clinical Trial Digitization Market Scenario

According to Data Bridge Market Research the market for pharma clinical trial digitization is increasing owing to the penetration of technology in the clinical research. The adoption of patient-centric remote and virtual trial design and direct-to-patient home services is helping the pharma clinical trial digitization to expand. Germination of health problems day by day is catering a good demand of research and technology, which on the whole is basic and keen parameter aiding to pharma clinical trial digitization market growth during the forecast period of 2020 to 2027.

Now the question is which are the other regions intuitive is targeting? Data Bridge Market Research has forecasted a large growth in theNorth America, owing to the advanced healthcare infrastructure. On the contrary Asia-Pacific (APAC) is expected to bounce the market growth exponentially due to surging players penetration and government initiatives taken.

Table of Contents-Snapshot Executive SummaryChapter 1 Industry OverviewChapter 2 Industry Competition by ManufacturersChapter 3 Industry Production Market Share by RegionsChapter 4 Industry Consumption by RegionsChapter 5 Industry Production, Revenue, Price Trend by TypeChapter 6 Industry Analysis by ApplicationsChapter 7 Company Profiles and Key Figures in Industry BusinessChapter 8 Industry Manufacturing Cost AnalysisChapter 9 Marketing Channel, Distributors and CustomersChapter 10 Market DynamicsChapter 11 Industry ForecastChapter 12 Research Findings and ConclusionChapter 13 Methodology and Data Source

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-pharma-clinical-trial-digitization-market&pm

Global Pharma Clinical Trial Digitization Market Scope and Market Size

Pharma clinical trial digitizationmarket is segmented of the basis of services, application and themes. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of services, the pharma clinical trial digitization market is segmented into drug dose adjustment, drug impact monitoring, medical prescription system, bioprinting, preventive therapy, and individualized drug printing.Based on application, the market is segmented into clinical data management, trial monitoring, patient recruitment and enrollment.The pharma clinical trial digitization market on the basis of theme is segmented into digital continuity across clinical trial it systems, patient-centric remote and virtual trial design and direct-to-patient home services.

Pharma Clinical Trial Digitization Market Country Level Analysis

Pharma clinical trial digitization market is analysed and market size insights and trends are provided by services, application and themes as referenced above.

The countries covered in the pharma clinical trial digitization market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The country section of the pharma clinical trial digitization market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Pharma clinical trial digitization market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for pharma clinical trial digitization market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the pharma clinical trial digitization market. The data is available for historic period 2010 to 2018.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

See the article here:
Pharma Clinical Trial Digitization Market 2021 Rising Demand and Grow Opportunities Antidote Technologies, Aparito, Clinerion, CliniOps, Inc., KSU |...

Read More...

Worldwide Point of Care (PoC) Molecular Diagnostics Industry to 2030 – Impact Analysis of COVID-19 – ResearchAndMarkets.com – Business Wire

February 17th, 2021 1:54 am

DUBLIN--(BUSINESS WIRE)--The "Global Point of Care (PoC) Molecular Diagnostics Market 2020-2030 by Product (Assays, Instruments, Software), Technology (PCR, INAAT, Microarray), Application, End User, and Region: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's offering.

The global PoC molecular diagnostics market will reach $5,665.3 million by 2030, growing by 13.5% annually over 2020-2030 driven by increase in adoption of personalized medicine and surge in usage of PoC molecular diagnostics for drug discovery and development amid COVID-19 pandemic.

This report is based on a comprehensive research of the entire global PoC molecular diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.

In-depth qualitative analyses include identification and investigation of the following aspects:

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global PoC molecular diagnostics market in every aspect of the classification from perspectives of Product, Technology, Application, End User, and Region.

Key Players:

Key Topics Covered:

1 Introduction

1.1 Industry Definition and Research Scope

1.1.1 Industry Definition

1.1.2 Research Scope

1.2 Research Methodology

1.2.1 Overview of Market Research Methodology

1.2.2 Market Assumption

1.2.3 Secondary Data

1.2.4 Primary Data

1.2.5 Data Filtration and Model Design

1.2.6 Market Size/Share Estimation

1.2.7 Research Limitations

1.3 Executive Summary

2 Market Overview and Dynamics

2.1 Market Size and Forecast

2.1.1 Impact of COVID-19 on World Economy

2.1.2 Impact of COVID-19 on the Market

2.2 Major Growth Drivers

2.3 Market Restraints and Challenges

2.4 Emerging Opportunities and Market Trends

2.5 Porter's Five Forces Analysis

3 Segmentation of Global Market by Product

3.1 Market Overview by Product

3.2 Kits & Assays

3.3 Analyzers & Instruments

3.4 Software & Services

4 Segmentation of Global Market by Technology

4.1 Market Overview by Technology

4.2 Polymerase Chain Reaction (PCR)

4.2.1 Real-Time PCR (rt-PCR)

4.2.2 Digital PCR (d-PCR)

4.3 Isothermal Nucleic Acid Amplification Technology (INAAT)

4.4 Genetic Sequencing-based Technology

4.5 Microarray-based Technology

4.6 Other Technologies

5 Segmentation of Global Market by Application

5.1 Market Overview by Application

5.2 Infectious Disease

5.2.1 Respiratory Infections

5.2.2 Hospital Acquired Infections

5.2.3 Sexually Transmitted Infections

5.3 Gastrointestinal Infections

5.4 Oncology

5.5 Hepatitis

5.6 Prenatal/Neonatal Testing

5.7 Other Applications

6 Segmentation of Global Market by End User

6.1 Market Overview by End User

6.2 Hospitals

6.3 Clinics & Diagnostic Centers

6.4 Research and Academic Institutes

6.5 Other End Users

7 Segmentation of Global Market by Region

7.1 Geographic Market Overview 2019-2030

7.2 North America Market 2019-2030 by Country

7.2.1 Overview of North America Market

7.2.2 U.S.

7.2.3 Canada

7.2.4 Mexico

7.3 European Market 2019-2030 by Country

7.3.1 Overview of European Market

7.3.2 Germany

7.3.3 UK

7.3.4 France

7.3.5 Spain

7.3.6 Italy

7.3.7 Russia

7.3.8 Rest of European Market

7.4 Asia-Pacific Market 2019-2030 by Country

7.4.1 Overview of Asia-Pacific Market

7.4.2 Japan

7.4.3 China

7.4.4 Australia

7.4.5 India

7.4.6 South Korea

7.4.7 Rest of APAC Region

7.5 South America Market 2019-2030 by Country

7.5.1 Argentina

7.5.2 Brazil

7.5.3 Chile

7.5.4 Rest of South America Market

7.6 MEA Market 2019-2030 by Country

7.6.1 UAE

7.6.2 Saudi Arabia

7.6.3 South Africa

7.6.4 Other National Markets

8 Competitive Landscape

8.1 Overview of Key Vendors

8.2 New Product Launch, Partnership, Investment, and M&A

8.3 Company Profiles

9 Investing in Global Market: Risk Assessment and Management

9.1 Risk Evaluation of Global Market

9.2 Critical Success Factors (CSFs)

Originally posted here:
Worldwide Point of Care (PoC) Molecular Diagnostics Industry to 2030 - Impact Analysis of COVID-19 - ResearchAndMarkets.com - Business Wire

Read More...

Pharma Clinical Trial Digitization Industry 2021 With Covid-19 Impact on Market Research by Size, Top Leading Countries, Companies, Consumption,…

February 17th, 2021 1:54 am

A New Business Research Report released by DBMR with title Global Pharma Clinical Trial Digitization Market Study Forecast till 2027. This Report presents detailed competitive analysis including the market share, size, growth, trends, demand, revenue, cost structure, segment and future scope 2027. This study categorizes the global Health and Safety Products breakdown data by manufacturers, region, type and applications, also analyzes the market drivers, opportunities and challenges. This Global Pharma Clinical Trial Digitization market report brings data for the estimated year 2021 and forecasted till 2027 in terms of both, value (US$ MN) and volume (MT). The report also consists of forecast factors, macroeconomic factors, and a market outlook of the Pharma Clinical Trial Digitization market. The study is conducted by applying both top-down and bottom-up approaches and further iterative methods used to validate and size market estimation and trends of the Global Pharma Clinical Trial Digitization market. Pharma Clinical Trial Digitization Market Report will add the analysis of the impact of COVID-19 on this industry.

Get Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharma-clinical-trial-digitization-market&aB

This upgradation of healthcare IT infrastructure and technological assistance being provided on vast scale is driving the market growth at the rate of 5.70% annual for the mentioned seven years. This momentum will be maintained by rising practice of individualized drug printing.

Data Bridge Market Research analyses the market to grow at a CAGR of 5.7% in the above-mentioned forecast period. Growing demand for personalized medicine is expected to create new opportunity for the pharma clinical trial digitization mark

Pharma Clinical Trial Digitization Market Overview:

Clinical trial digitization allows the processing in different forms of voluminous patient-related data. Such data are being used by pharmaceutical companies to improve the effectiveness of trial execution.

Growing demand for quality data is expected to drive the market growth. Some of the other factors such as increasing demand for personalized drugs, increasing adoption of new technology in clinical research, growing research & development promoting outsourcing and increasing diseases prevalence will drive the market in the forecast period of 2020 to 2027

Global Pharma Clinical Trial Digitization Market 2020 Reportencompasses an infinite knowledge and information on what the markets definition, classifications, applications, and engagements are and also explains the drivers and restraints of the market which is obtained from SWOT analysis. By applying market intelligence for this Pharma Clinical Trial Digitization Market report, industry expert measure strategic options, summarize successful action plans and support companies with critical bottom-line decisions. Additionally, the data, facts and figures collected to generate this market report are obtained forms the trustworthy sources such as websites, journals, mergers, newspapers and other authentic sources. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

According to this report Global Pharma Clinical Trial Digitization Market will rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Pharma Clinical Trial Digitization Market includes comprehensive information derived from depth study on Pharma Clinical Trial Digitization Industry historical and forecast market data. Global Pharma Clinical Trial Digitization Market Size To Expand moderately as the new developments in Pharma Clinical Trial Digitization and Impact of COVID19 over the forecast period 2020 to 2027.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT, GET FREE COVID-19 SAMPLE @https://www.databridgemarketresearch.com/covid-19-impact/global-pharma-clinical-trial-digitization-market?ab

Pharma Clinical Trial Digitization Market report provides depth analysis of the market impact and new opportunities created by the COVID19/CORONA Virus pandemic. Report covers Pharma Clinical Trial Digitization Market report is helpful for strategists, marketers and senior management, And Key Players in Pharma Clinical Trial Digitization Industry.

Pharma Clinical Trial Digitization Market Segments Outlook:

By Services (Drug Dose Adjustment, Drug Impact Monitoring, Medical Prescription System, Bioprinting, Preventive Therapy, Individualized Drug Printing)

By Application (Clinical Data Management, Trial Monitoring, Patient Recruitment and Enrollment)

By Themes (Digital Continuity Across Clinical Trial IT Systems, Patient-centric Remote and Virtual Trial Design, Direct-to-patient Home Services)

List of Companies Profiled in the Pharma Clinical Trial Digitization Market Report are:

Antidote Technologies, Inc.AparitoClinerion Ltd.CliniOps, Inc.ConsilxDeep 6 AIKoneksa Health Inc.Medidata SolutionsOraclePatientsLikeMeTrialbeeTriNetX, Inc.Veeva SystemsComplete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @https://www.databridgemarketresearch.com/toc/?dbmr=global-pharma-clinical-trial-digitization-market&Ab

Pharma Clinical Trial Digitization Reportdisplays data on key players, majorcollaborations, merger & acquisitions along with trending innovation and business policies. The report highlights current and future market trends and carries out analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Pharma Clinical Trial Digitization market report include market definition, market segmentation, key developments, competitive analysis and research methodology. To accomplish maximum return on investment (ROI), its very essential to be acquainted with market parameters such as brand awareness, market landscape, possible future issues, industry trends and customer behavior where this Pharma Clinical Trial Digitization report comes into play.

Global Pharma Clinical Trial Digitization Market Scope and Market Size

On the basis of services, the pharma clinical trial digitization market is segmented into drug dose adjustment, drug impact monitoring, medical prescription system, bioprinting, preventive therapy, and individualized drug printing.

Based on application, the market is segmented into clinical data management, trial monitoring, patient recruitment and enrollment.

The pharma clinical trial digitization market on the basis of theme is segmented into digital continuity across clinical trial it systems, patient-centric remote and virtual trial design and direct-to-patient home services.

Market Size Segmentation by Region & Countries (Customizable):

North America (Canada, United States & Mexico)Europe (Germany, the United Kingdom, Benelux, France, Russia & Italy)Asia-Pacific (Japan, South Korea, China, India & Southeast Asia)South America (Argentina, Brazil, Peru, Colombia, Etc.)Middle East & Africa (United Arab Emirates, Egypt, Saudi Arabia, Nigeria & South Africa)Key Questions Answered

What impact does COVID-19 have made on Global Pharma Clinical Trial Digitization Market Growth & Sizing?

Who are the Leading key players and what are their Key Business plans in the Global Pharma Clinical Trial Digitization market?

What are the key concerns of the five forces analysis of the Global Pharma Clinical Trial Digitization market?

What are different prospects and threats faced by the dealers in the Global Pharma Clinical Trial Digitization market?

What are the strengths and weaknesses of the key vendors?

Major Key Contents Covered in Pharma Clinical Trial Digitization Market:

Introduction of Pharma Clinical Trial Digitization with development and status.

Manufacturing Technology of Pharma Clinical Trial Digitization with analysis and trends.

Analysis of Global Pharma Clinical Trial Digitization market Key Manufacturers with Company Profile, Product Information, Production Information, and Contact Information.

Analysis of Global Pharma Clinical Trial Digitization market Capacity, Production, Production Value, Cost and Profit

Analysis Pharma Clinical Trial Digitization Market with Comparison, Supply, Consumption, and Import and Export.

Pharma Clinical Trial Digitization market Analysis with Market Status and Market Competition by Companies and Countries.

2020-2027 Market Forecast of Global Pharma Clinical Trial Digitization Market with Cost, Profit, Market Shares, Supply, Demands, Import and Export

Trending factors influencing the market shares of APAC, Europe, North America, and ROW?

Pharma Clinical Trial Digitization Market Analysis of Industry Chain Structure, Upstream Raw Materials, Downstream Industry

Strategic Points Covered in Table of Content of Global Pharma Clinical Trial Digitization Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Pharma Clinical Trial Digitization market

Chapter 2: Exclusive Summary the basic information of the Pharma Clinical Trial Digitization Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Pharma Clinical Trial Digitization

Chapter 4: Presenting the Pharma Clinical Trial Digitization Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2010-2019

Chapter 6: Evaluating the leading manufacturers of the Pharma Clinical Trial Digitization market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2020-2027).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Pharma Clinical Trial Digitization Market is a valuable source of guidance for individuals and companies in decision framework.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

View original post here:
Pharma Clinical Trial Digitization Industry 2021 With Covid-19 Impact on Market Research by Size, Top Leading Countries, Companies, Consumption,...

Read More...

A Guide to Disability Benefits and Psoriatic Arthritis – Healthline

February 17th, 2021 1:52 am

Psoriatic arthritis (PsA) is a condition that can be particularly debilitating and painful, causing intense flare-ups that cause joints to be become inflamed.

This can make mobility difficult sometimes impossible. Not surprisingly, that can affect the ability to work, no matter your profession.

Although people with PsA can have long periods of remission, with few symptoms or even none, the unpredictability of the condition could require extended periods away from a job, or hinder your ability to look for employment.

According to a 2016 study, one-third of people with PsA reported missing work because of their disease, and the condition impacted their ability to work full-time.

Disability insurance may be able to replace some of that income.

Social Security Disability Income (SSDI) is a federal disability insurance benefit for those who have paid into Social Security while working.

If youre in a low-income bracket and havent paid enough into Social Security during your working years to qualify for SSDI, youre not out of luck. In that case, you may be a candidate for a different program called supplemental security income (SSI).

For both SSDI and SSI, benefits are limited to people who fall under the definition of being unable to perform substantial, gainful activity, says Liz Supinski, director of data science at the Society for Human Resource Management.

There are limits on how much a person can earn and still collect, she adds about $1,200 for most people, or around $2,000 per month for blind people.

Some people are covered by private disability insurance, typically acquired through their work, Supinski says.

Having this type of insurance doesnt disqualify you from receiving SSDI, because its usually a short-term benefit with more limited amounts. Because of that, she notes that many people use this insurance to replace income as theyre navigating through the SSDI process.

The Social Security Administration (SSA) categorizes PsA under the classification of immune system impairments, and specifically under sections 14.00D6 and 14.09 as Inflammatory Arthritis.

This encompasses a spectrum of inflammatory arthritis conditions, but all with the main challenge of limiting your movements, mainly through joint pain, swelling, and tenderness.

In addition to PsA, this description could include other conditions like inflammatory bowel disease (IBD), ankylosing spondylitis, and reactive arthritis, also known as Reiters syndrome.

The SSA evaluates the severity of the condition in order to approve disability benefits and acknowledges that your PsA may involve other systems as well, such as:

Because your disability claim is likely to include these types of concerns as well as complications of joint inflammation, its essential to have your medical paperwork together, including insights from your primary care doctor and specialists.

You can apply for disability benefits while youre still employed if your symptoms are significantly impacting your work, although most people tend to apply once theyve left a position, possibly because of their condition, says Supinski.

Whether you have PsA, a different condition, or a combination of conditions, the process for establishing a disability claim will be much more streamlined if you have a breadth of information already in place, says Michelle Ogunwole, MD, a specialist in internal medicine and research fellow at The Johns Hopkins University School of Medicine.

If youre managing multiple health issues or a chronic condition like psoriatic arthritis, its already a good idea to compile your medical info in one place, so you have it available for appointments, she says.

That will also give you insight into trends you may not have been seeing before, like possible triggers for a flare-up, she adds.

If possible, have the following information on hand:

Also, let your doctors, colleagues, and family know youll be going through the application process. The SSA gathers input from healthcare providers as well as the applicant and sometimes asks for additional information from family members and co-workers to determine if you qualify as disabled based on SSA criteria.

Claiming disability benefits can be a complex and lengthy process, but taking the time to understand the criteria used by the SSA can help you get closer to getting a claim approved.

Consider reaching out to representatives at your local SSA field office, since they can help you apply for SSDI and SSI benefits.

Make an appointment by calling 800-772-1213, or you can also complete an application online at the SSA website.

Elizabeth Millard lives in Minnesota with her partner, Karla, and their menagerie of farm animals. Her work has appeared in a variety of publications, including SELF, Everyday Health, HealthCentral, Runners World, Prevention, Livestrong, Medscape, and many others. You can find her and way too many cat photos on her Instagram.

Read the rest here:
A Guide to Disability Benefits and Psoriatic Arthritis - Healthline

Read More...

Drug used to treat arthritis could save the lives of those sickest from COVID-19, study finds – ABC Action News

February 17th, 2021 1:52 am

TAMPA, Fla. A drug used for nearly a decade to prevent joint pain and swelling in those with arthritis could save your life from COVID-19. A new study is showing promising results with those sickest from the coronavirus.

Theres a promising drug doctors are using right now to treat the sickest of the sick. Its called Tocilizumab under the brand name Actembra.

This is basically another tool in the toolbox for us to help prevent people from getting severe COVID and die," said Dr. Michael Teng, a virologist at USF Health.

The antibody has been used to lessen the inflammation in patients with rheumatoid arthritis for nearly a decade now.

Preliminary findings of the RECOVERY Trial out of the U.K. show Tocilizumab also reduces the risk of death, shortens the amount of time someone is in the hospital and lessens the need for a ventilator.

If you get infected and have severe COVID now there's an additional drug that can help you survive," said Dr. Teng.

The same trial by the University of Oxford first discovered Dexamethasone was effective in fighting COVID.

So they've [researchers] tried things like anti-HIV drugs, which didn't work very well. They tried hydroxychloroquine and the study showed it didn't work very well," said Dr. Teng.

Dexamethasone was used on former President Donald Trump. Now it's part of standard care. Meanwhile, Tocilizumab would provide it a boost. The study shows for every 25 patients treated with the drug, one additional life would have been saved.

But is it necessary with millions of Americans now getting vaccinated? Doctor Teng insists it absolutely is necessary.

Only about 4% of our population has gotten both doses of vaccine. So that means there's a lot of people out there that are still susceptible to coronavirus infection.

Dr. Teng warns there are downsides to the drug.

It's expensive, it's not that widely available," he said.

Nonetheless, he believes, any tool to help in the fight against the pandemic is always welcome.

See original here:
Drug used to treat arthritis could save the lives of those sickest from COVID-19, study finds - ABC Action News

Read More...

How Does Abatacept Compare To Other bDMARDs in Rheumatoid Arthritis Treatment? – DocWire News

February 17th, 2021 1:52 am

A study evaluated the use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of rheumatoid arthritis (RA), and compared outcomes between patients taking abatacept compared to other bDMARDs.

The retrospective study included patients with RA treated with abatacept as any line of therapy (LOT) at four different centers in the UK between January 2013 and December 2017.

Final analysis consisted of 213 patients who received up to eight LOTs. The mean age was 55.2 years, and most patients were female (71.4%). The median disease duration prior to initiating bDMARD therapy was 3.9 years (interquartile range, 2.1-8.5 years). Receipt of abatacept or any bDMARD was correlated with reduced six-month disease activity score for 28 joints (DAS28) erythrocyte sedimentation rate and DAS2 C-reactive protein (DAS28-CRP) scores. European League Against Rheumatism (EULAR) responses, measured as good, moderate, or no response, were better for patients when receiving abatacept compared to when receiving other bDMARDs, at six months (22.8% vs. 16.6%, 41.3% vs. 41.4%, and 35.9% vs. 42.1%, respectively) and one year (27.9% vs. 21.2%, 36.1% vs. 34.5%, and 36.1% vs. 44.2%, respectively).

The 68 patients who received abatacept as their first LOT were on treatment much longer compared to those receiving other bDMARDs (53.4 months vs. 17.4 months, P<0.01), and this was similar for the second LOT. Patients receiving other bDMARDs who stopped after six months were more likely to sustain an infection requiring antibiotics compared to patients receiving abatacept.

The study was published in BMC Rheumatology.

The researchers acknowledged the impact of the COVID-19 pandemic on treatment as well.

The rheumatology community is working to optimise disease management strategies and transition to telehealth. Early research suggests the risk of serious complications from COVID-19 is not increased for patients treated with bDMARDs or targeted synethic DMARDs. However, preventative withdrawal of these treatments, which may occur at the time of COVID-19 symptom onset, should be avoided due to the increased risk of relapse and morbidity. Future research should consider how abatacept and other bDMARDs are used in RA management during and after the pandemic, they recommended.

See the original post here:
How Does Abatacept Compare To Other bDMARDs in Rheumatoid Arthritis Treatment? - DocWire News

Read More...

Arthritis Knee Pain Centers Offers Therapy That Helps Reduce Osteoarthritis Knee Pain and Increase Mobility – Press Release – Digital Journal

February 17th, 2021 1:52 am

The medical practice group provides a non-surgical, non-opioid, outpatient pain relief program to patients around the country.

Osteoarthritis (OA) is the most common type of arthritis and affects more than 32 million adults in the United States alone. Known as the wear and tear arthritis, it occurs when the smooth cushion or the cartilage between bones breaks down, and causes joints to become painful, swollen and hard to move. The knee joint is the most common area for OA to strike and millions of people are hobbled by the debilitating pain, prohibiting them from carrying out everyday activities like climbing stairs, standing up from a seated position, or even standing for an extended amount of time.

Besides the challenge of managing the chronic pain, the consequential immobility and inactivity exacerbates other serious conditions such as obesity, diabetes, and heart disease. Arthritis Knee Pain Centers provides a comprehensive program that can help reduce pain and increase mobility without surgery or opioids.

Headquarted in Spring, Texas, Arthritis Knee Pain Centers growing network has practices all over the US. They specialize in a minimally invasive therapy designed to replenish depleted joint fluids with an FDA-approved cushioning gel. They use advanced digital imaging for precision placement, removing the guesswork that many of todays practitioners rely on to treat knee and joint pain.

Our singular clinical focus on treating osteoarthritis of the knee combined with our utilization of cutting-edge technology has allowed our specially trained physicians to excel at relieving the often debilitating chronic pain of our patients, says Dr. John J. Rush, Chief Medical Officer of Arthritis Knee Pain Centers. Weve successfully treated more than 20,000 patients since 2016.

Recognizing early warning signs of osteoarthritis can help slow down its progression. Some of its early warning signs are pain; stiffness and loss of flexibility; as well as a scraping or grating sensation when moving the knees. There are many ways that can help reduce the pain and the need for pain medication. Exercise and weight loss; physical therapy; and precision guided injections are some of the ways that can help manage osteoarthritis.

For more information on Arthritis Knee Pain Centers and osteoarthritis, visithttps://www.arthritiskneepain.com.

About Arthritis Knee Pain Centers

Arthritis Knee Pain Centers is a medical practice group that specializes in an FDA-approved pain relief therapy designed to help osteoarthritis sufferers decrease their knee joint pain. Headquartered in Spring, Texas, Arthritis Knee Pain Centers has practices in Texas, New York, Kentucky, Arizona, Ohio, North Carolina, South Carolina, and New Jersey.

Media ContactCompany Name: Arthritis Knee Pain CentersContact Person: Teresa JeffersonEmail: Send EmailPhone: 202-596-9229Country: United StatesWebsite: https://www.arthritiskneepain.com/

Read the rest here:
Arthritis Knee Pain Centers Offers Therapy That Helps Reduce Osteoarthritis Knee Pain and Increase Mobility - Press Release - Digital Journal

Read More...

Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab,…

February 17th, 2021 1:52 am

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that on February 11th, the European Commission (EC) has granted marketing authorisation for Yuflyma (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for the treatment of multiple chronic inflammatory diseases.

The EC approval of Yuflyma follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in December 2020. The marketing authorisation is based on analytical, preclinical and clinical studies, demonstrating that Yuflyma is comparable to adalimumab, the reference product, in terms of safety, efficacy, PK/PD and immunogenicity up to 24 weeks1 and 1 year2 following treatment. Based on the results of the pivotal study, a high concentration formulation of Yuflyma has been approved for use in the European Union (EU), in patients with thirteen chronic inflammatory diseases; rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), psoriatic arthritis (PsA), psoriasis (PsO), paediatric plaque psoriasis (pPsO), hidradenitis suppurativa (HS), Crohns disease (CD), paediatric Crohns disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV).

In Europe, according to IQVIA data, 60% of the whole adalimumab market has been taken by high concentration formulation and over 90% of the original adalimumab market has already been replaced with a high concentration version. With high concentration, low-volume, and consequently less pain, adalimumab can improve treatment adherence at the very least. Therefore, we focused on development of a high concentration biosimilar to provide a significant alternative to the adalimumab treatment category, said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. In terms of the administration device, we have looked to ensure improved convenience for patients as well as providers with the inclusion of needle size (29G), latex-free to reduce allergy risk, and a long storage period or shelf life at room temperature for 30 days.

Professor Rieke Alten, Head of the Department of Internal Medicine, Rheumatology, Clinical Immunology and Osteology at Schlosspark-Klinik, Teaching Hospital of Charit, Berlin, Germany said, Over the past two decades, anti-tumour necrosis factor (TNF) biologics have revolutionised the management of chronic immune-mediated inflammatory diseases, but some of the features needed improvement for patients to reach their therapeutic goals. As a physician, we welcome these value-added features such as high concentration and low-volume formulations to reduce injection discomfort.

The centralised marketing authorisation granted by the EC is valid in all EU Member States as well as in the European Economic Area countries Iceland, Liechtenstein and Norway. This announcement will enable affordable access to a high concentration adalimumab biosimilar, broadening treatment alternatives for patients suffering with chronic inflammatory disease including rheumatoid arthritis, psoriasis, Crohns disease and ulcerative colitis.

Celltrion will take the EC Decision Reliance Procedure (ECDRP) to minimise lead time to launch the product in the UK and remains committed to delivering innovative and affordable medications to promote patients access to advanced therapies.

- ENDS -

Notes to Editors:

About CT-P17 (biosimilar adalimumab)

CT-P17 is the first proposed high concentration, low- volume and citrate-free adalimumab biosimilar. CT-P17 is indicated for the treatment of patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), psoriatic arthritis (PsA), psoriasis (Ps), paediatric plaque psoriasis (pPs), hidradenitis suppurativa (HS), Crohns disease (CD), paediatric Crohns disease (pCD), ulcerative colitis (UC), uveitis (UV) and paediatric uveitis (pUV). CT-P17 is a recombinant human monoclonal antibody that contains the active ingredient adalimumab. Adalimumab is a fully human antitumour necrosis factor (anti-TNF) monoclonal antibody. CT-P17 provides pain-reducing features as it comes with citrate-free formulation, meaning it causes less pain upon injection.

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us

References

1 J. Kay., et al. (2020). A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis. Poster Presented at ACR Convergence 20202 Data on file

Read more here:
Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab,...

Read More...

Scottish university teams up with US pharmaceuticals giant for research on immunological diseases, including arthritis – HeraldScotland

February 17th, 2021 1:52 am

THE University of Glasgow is embarking on a 4.6 million, four-year research collaboration with US-based pharmaceuticals group Eli Lilly and Company to discover and validate the next generation of drug targets for immunological diseases.

Led by the universitys Institute of Infection, Immunity and Inflammation, the collaboration will work across four diseases: psoriatic arthritis, rheumatoid arthritis, fibrosis, and vasculitis.

The university said it was hoped the collaboration between its scientists and those of Lilly would help enable the identification of first-in-class therapeutics for people suffering with these devastating and costly conditions.

READ MORE:Ian McConnell: Brexit could have taken many forms. Cheshire Cat Boris Johnson chose this one

It added: Rheumatoid arthritis alone affects 0.3 per cent to 1% of people across the globe and it is estimated that, within ten years of diagnosis, 40% of people will be unable to stay in full-time work. This has major socio-economic repercussions. In the UK, this costs the NHS on average 700 million per year and indirectly costs the UK economy an estimated 8 billion per year.

University of Glasgow principal Professor Sir Anton Muscatelli said: Glasgows researchers have a vision to drive forward innovation, in order to tackle some of societys most urgent challenges. The Glasgow-Lilly collaboration is well positioned to be an inspiring example of this vision and of the exciting possibilities of industry and academia working together. I look forward to seeing this important partnership progress, advancing the next generation of first-in-class therapeutic agents and their alignment with precision medicine approaches.

READ MORE:Brexit: Ian McConnell: The inconvenient truths for think big Boris Johnson, flagged by Emmanuel Macron and Danny Blanchflower

The University of Glasgow team is led by Carl Goodyear, and includes Stefan Siebert, Mariola Kurowska-Stolarska, Neal Millar, Neil Basu and Thomas Otto.

Ajay Nirula, vice-president of immunology at Lilly, said: Lillys research efforts continue to expand beyond our own laboratories to include unique partnerships with top academic institutions such as the University of Glasgow. We look forward to collaborating closely with the scientific team at UofG to discover potential new therapies for immunological disorders.

Link:
Scottish university teams up with US pharmaceuticals giant for research on immunological diseases, including arthritis - HeraldScotland

Read More...

Google News’ "Genetics" Section Is Full of Articles About People Named Gene – Futurism

February 14th, 2021 7:30 pm

Why is Google pulling up "Genetics" stories about Gene Simmons?Celebrity Gossip

If you try to look up the latest genetics news on Google News right now, youll find less information on the latest biomedical research and perhaps a little bit more about celebrities than you expected.

Google News algorithm seems to be pulling stories about people named Gene into the mix the news feed is full of articles about KISS frontman Gene Simmons, comedian Amy Schumers son Gene, and former National Economic Council Director Gene Sperling. Its a harmless glitch, to be sure, but also a bit puzzling given Googles global leadership in the AI industry.

A Google spokesperson told Futurism that theyre going to look into this, but didnt clarify what went wrong with the Google News algorithm or why.

But from an outsiders perspective, it seems like someone at Google told the algorithm to feature stories that have the word gene in their headline without checking whether they talk about music icons or cellular biology. To be fair, it gets confusing.

Well let you know if Google gets back to us, but the more likely outcome is that the glitch gets quietly fixed without Google announcing that something went wrong. Still, were holding out hope that well learn about some intern who accidentally cranked a big lever with Gene news written on it all the way up or something like that.

In the meantime, feel free to enjoy the feed of carefully-curated biomedical and KISS news that Google put together.

More on questionable science news: This Awful Tabloid Predicts a Killer Asteroid Almost Every Day

More here:
Google News' "Genetics" Section Is Full of Articles About People Named Gene - Futurism

Read More...

Global Animal Genetics Market Forecast to 2027 by Product (Poultry, Porcine, Bovine, Canine), Material (Semen and Embryo), and Services (DNA Typing,…

February 14th, 2021 7:30 pm

DUBLIN--(BUSINESS WIRE)--The "Animal Genetics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product (Poultry, Porcine, Bovine, Canine, and Others), Genetic Material (Semen and Embryo), and Services (DNA Typing, Genetic Trait Tests, Genetic Disease Tests, and Others) and Geography." report has been added to ResearchAndMarkets.com's offering.

Genetic material and Services the market is expected to reach US$ 7,705.23 million by 2027 from US$ 4,778.67 million in 2019. The market is estimated to grow at a CAGR of 6.3% from 2020 to 2027.

Based on product, the market is segmented into poultry, porcine, bovine, canine, and others. In 2019, the porcine segment accounted for the highest share of the market. Growth of this segment is attributed to rise in production of porcine and increase in pork consumption across the globe. The same segment is likely to register highest CAGR in the global animal genetics market during the forecast period.

In terms of genetic material, the animal genetics market is segmented into embryo and semen. The embryo segment held the largest share of the market in 2019, whereas the semen segment is anticipated to register the highest CAGR of 7.0% in the market during the forecast period.

COVID-19 pandemic has become the most significant challenge across the world. This challenge would be frightening, especially in developing countries across the globe, as it may lead to reducing imports due to disruptions in global trade, which further increases the shortages of meat and dairy product supplies, resulting in a considerable price increase. Asian countries such as China, South Korea, and India are severely affected due to COVID-19 outbreak.

NEOGEN Corporation, HENDRIX GENETICS BV, Zoetis Inc., Genus, TOPIGS NORSVIN, Envigo, VetGen, ANIMAL GENETICS INC., ALTA GENETICS INC., and Groupe Grimaud are among the leading companies operating in the animal genetics market.

Key Topics Covered:

1. Introduction

1.1 Scope of the Study

1.2 Report Guidance

1.3 Market Segmentation

2. Animal Genetics Market - Key Takeaways

3. Research Methodology

4. Animal Genetics Market - Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Expert Opinions

5. Animal Genetics Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Growing Preference for Animal Derived Proteins Supplements and Food Products.

5.1.2 Rising Adoption of Progressive Genetic Practices Such as Artificial Insemination (AI) and Embryo Transfer

5.2 Market Restraints

5.2.1 Limited Number of Skilled Professionals in Veterinary Research

5.2.2 Stringent Government Regulations for Animal Genetics

5.3 Market Opportunities

5.3.1 Innovations in Phenotyping Services

5.4 Future Trends

5.4.1 Significant Investments in R&D and Expansions Undertaken by Market Players

5.5 Impact Analysis

6. Animal Genetics Market - Global Analysis

6.1 Global Animal Genetics Marker Revenue Forecast and Analysis

6.2 Global Animal Genetics Market, By Geography - Forecast And Analysis

6.3 Market Positioning of Key Players

7. Animal Genetics Market Analysis - By Product

7.1 Overview

7.2 Animal Genetics Market Revenue Share, by Product (2019 and 2027)

7.3 Poultry

7.4 Porcine

7.5 Bovine

7.6 Canine

8. Animal Genetics Market Analysis - By Genetic Material

8.1 Overview

8.2 Animal Genetics Market Revenue Share, by Genetic Material(2019 and 2027)

8.3 Semen

8.4 Embryo

9. Animal Genetics Market Analysis - By Service

9.1 Overview

9.2 Animal Genetics Market Share, by Service, 2019 and 2027, (%)

9.3 DNA Typing

9.4 Genetic Trait Tests

9.5 Genetic Disease Tests

10. Animal Genetics Market Analysis and Forecasts To 2027 - Geographical Analysis

11. Impact of COVID-19 Pandemic On Global Animal Genetics Market

11.1 North America: Impact Assessment of COVID-19 Pandemic

11.2 Europe: Impact Assessment of COVID-19 Pandemic

11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market, (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/6ynx7z

View post:
Global Animal Genetics Market Forecast to 2027 by Product (Poultry, Porcine, Bovine, Canine), Material (Semen and Embryo), and Services (DNA Typing,...

Read More...

Genetics the next frontier of healthcare – Bangkok Post – Bangkok Post

February 14th, 2021 7:30 pm

China is banking on genetics as the next frontier of modern healthcare. From genetic testing and sequencing to gene therapy and precision medicine, this range of transformative technologies and services can underpin medical treatments and inform lifestyle choices.

Precision medicine -- using genetic information to determine treatments -- enables healthcare to move away from a one-size-fits-all approach where patients are treated with the same therapy, to one where targeted treatments are based on a patient's DNA and biomarkers.

The Chinese government and private sector are leading the charge globally, encouraging nationwide collection of DNA samples and investing in data analysis tools.

The Beijing Genome Institute, the world's largest sequencer and repository of genetic material, says it is capable of decoding the entire genomes of 100,000 people a year for no more than US$100 per person. In 2017, genetic testing was listed in China's 13th Five-Year Plan as one of the key growth strategies for the life sciences sector.

While some companies continue to work on breakthrough technology for whole-genome sequencing, others are focusing on the direct-to-consumer DNA test industry that only analyses small sections of a person's DNA. These consumer tests are marketed at younger people who are interested in their genealogy or are seeking health predictions and suggestions for lifestyle adjustments.

For as little as $3, you can provide a saliva sample to a company in exchange for information such as risks of developing chronic illnesses, how to lose weight and how to care for your skin. This market is expected to generate sales of $405 million in China by next year.

Last December, the consumer genetic testing company Genebox raised $14 million in financing. It has lowered the price a DNA test to 19.90 yuan ($3) since entering the market in 2018. More than 2.2 million people in China had used Genebox's service as of the end of 2019. This number is forecast to increase to 56.8 million by 2022, according to the consultancy Yi Ou.

As mass-market genetic testing becomes more commonplace, and the Chinese government ramps up efforts to develop its national DNA database, observers have raised the issue of privacy and personal data protection.

Companies such as Genebox have committed to not sharing personal information with third parties. However, exceptions exist, including having to comply with laws and regulations, as well as sharing user data with subsidiaries and related organisations for medical research and product development purposes.

Currently, China does not have specific legislation in place to protect personal data, including genetic data, at the national level. However, regulations are being developed. The Standing Committee of the National People's Congress of China has outlined a legislative agenda for a data protection law that is set to be enacted next year.

Overcoming data privacy concerns will be key to unleashing the full benefits of genetic testing. Structural efforts should be made to overcome these issues, such as transparency over how such powerful personal data is used. Close collaboration is needed between genetic testing companies, doctors, patient rights advocates, regulatory agencies and insurers.

Although precision medicine is still in its infancy, it is attracting great interest, including from Thailand. I hope the new privacy laws due to be introduced this year are broad enough to cover these emerging technologies so that we are ready to protect people once they become mainstream.

Link:
Genetics the next frontier of healthcare - Bangkok Post - Bangkok Post

Read More...

Front Range Biosciences Introduces A New Class of THCv Genetics That Will Boost Market Opportunities for New Consumer Experiences and Functional…

February 14th, 2021 7:30 pm

BOULDER, Colo., Feb. 9, 2021 /PRNewswire/ -- Front Range Biosciences ("FRB"), a cannabis and hemp genetics platform company, leveraging next generation breeding technology and R&D, todaybecame one of the first genetics providers to launch a new product line of high THCv plant varieties, in California, with availability in Colorado through licensed partners leveraging FRB's technology platform. This first generation product line is among the highest producers of THCv available, containing more than 20% total cannabinoids, more than 8% THCv, and over 2% grassy and fruity terpenes. These new varieties yield twice the yield of typical THCv producing plants. THCv is rare and has been an elusive minor cannabinoid until now, with exciting new properties for consumers that report appetite suppression and energizing, less psychoactive experiences.

"FRB is continually developing new genetics to help growers, brands, and consumers find new applications for cannabis," said Dr. Jonathan Vaught, CEO of Front Range Biosciences. "The cannabis market is evolving quickly, and consumers are constantly looking for new and unique experiences, just like in other CPG industries. We are leveraging genomics driven breeding to rapidly develop new products for cannabis companies and brands, unlocking new product opportunities from the incredible diversity of chemistry this plant produces. THCv represents just one of many new products we are making more accessible to the supply chain from this versatile plant through breeding, and we have many other unique products in development for other potential categories like edible ingredients, nutraceuticals and even pharmaceuticals.

This is the first THCv product line from FRB's world-renowned breeding program and expansive cannabis genetics library. This revolutionary THCv variety will pave the way for more unique consumer products, medical research and therapeutics. There is also a growing body of research linking THCv to a number of potential therapeutic benefits, including regulating tremors and seizures in ALS and Parkinson's patients, blocking fight or flight responses in PTSD, and acting as an effective analgesic for treating pain and migraines.

Since FRB's strain debuted on the market in California, it has become a favorite among local consumers. "It has a smooth, spicy-sweet smoke that creates a functional high. The THCv allows me to stay focused throughout the day, and I love that it's the opposite of most cannabis flower and keeps the munchies at bay," said Tricia Goldberg.

FRB's latest offering makes THCv more accessible by providing genetics that drastically increase yields, significantly reduce harvest times, deliver a variety of terpenes for improved flavor, as well as produce significantly higher levels of THCv, compared to the limited number of other THCv genetics that are currently available. These improvements in the finished product profile will open the door for new product opportunities for THCv flower-based products including smokable flower, pre-rolls, and concentrates, providing exciting new experiences for cannabis consumers.

"THCv, along with other minor cannabinoids, terpenes, and even flavonoids, have been a challenging group of traits for breeders to develop while maintaining the level of vigor and yield needed to introduce these products into the supply chain effectively," says Dr. Reggie Gaudino, VP of R&D for Front Range Biosciences. "The many years of genomics and chemistry research our team has been committed to for cannabis is allowing us to help growers and product companies do so much more with the plant than what was possible, even just a few years ago."

Growers have faced challenges producing cannabis containing high THCv content. The price of THCv has remained high due to significant lack of supply, and product availability has been extremely limited. This new class of THCv genetic products provides a timely solution to both issues, creating lucrative opportunities for cultivators and operators.

About Front Range Biosciences

Front Range Biosciences is a premier cannabis and hemp genetics platform company, creating and supporting innovative new products across multiple industries by combining next generation agricultural technologies with the world's top hemp and cannabis R&D program. FRB provides leading-edge solutions to growers, brands, and product manufacturers through its unique varieties of seeds, young plants, and technology licensing to drive product development and production efficiency for cannabis and hemp derived products. Since 2015, the company has been dedicated to creating new product opportunities and solving challenges throughout the supply chain by leveraging proprietary next generation breeding, chemistry, and tissue culture technologies. In addition to FRB's groundbreaking technology, the company has also established genetics services dedicated to the California market and a Shimadzu sponsored Hemp Center of Excellence with top-tier researchers to encourage further innovation in the industry. FRB is the company of choice for cultivators that demand unique, quality, consistent products. For more information on Front Range Biosciences, visit http://www.frontrangebio.com.

Media Contact

MATTIO Communications

frb@mattio.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/front-range-biosciences-introduces-a-new-class-of-thcv-genetics-that-will-boost-market-opportunities-for-new-consumer-experiences-and-functional-products-301224797.html

SOURCE Front Range Biosciences

Original post:
Front Range Biosciences Introduces A New Class of THCv Genetics That Will Boost Market Opportunities for New Consumer Experiences and Functional...

Read More...

Canine genetics, health to be explored at summit – VeterinaryPracticeNews.com

February 14th, 2021 7:30 pm

Preserving and enhancing genetic diversity in dog breeds is set to be explored at an upcoming virtual educational conference.

Scheduled for Feb. 15 and 16, Embark Veterinarys Canine Health Summit will feature presentations, panel discussions, and interactive sessions presented by various experts across the canine health landscape.

The free event, which targets veterinarians, breeders, and pet owners, will also include a keynote address by Duke University professor, Brian Hare, PhD, MA. Additionally, a roundtable discussion led by the Westminster Kennel Club will explore the history of purebred dogs, and how breeders and owners can work together to improve the long term health and vitality of specific breeds.

This summit is an opportunity to bring together a diverse group of stakeholders who are all committed to canine health and discuss ways to work together to accelerate the pace of discovery in the future, says Embarks chief science officer, Adam Boyko, PhD.

In lieu of registration fees, attendees are invited to contribute to the summits fundraiser, benefiting Morris Animal Foundation to support canine health research. Embark will also provide a matching donation of up to $5,000, the company says.

Morris Animal Foundation, as part of its research portfolio, has a long history of investing in canine genetics research to advance the health of dogs, says the foundations chief development officer, Ryan Welch. Were deeply appreciative of the generosity of Embark, and participants in the Canine Health Summit, for their contributions to help ensure this work continues.

To register, click here.

Originally posted here:
Canine genetics, health to be explored at summit - VeterinaryPracticeNews.com

Read More...

Genetic Origins of Canine Hip Dysplasia Evaluated in Validation Study – Business Wire

February 14th, 2021 7:30 pm

VANCOUVER, Wash.--(BUSINESS WIRE)--Wisdom Health Genetics, the world leader in pet genetics and maker of the WISDOM PANEL dog DNA test, announced today the publication in BMC Genomics of a study conducted in partnership with the University of Helsinki.

The studyAn across-breed validation study of 46 genetic markers in canine hip dysplasiaconfirms that canine hip dysplasia has a complex genetic origin.

Canine hip dysplasia is a common, painful health condition that affects many different dog breeds. Hip dysplasia is believed to result from both environmental and genetic factors; however, its genetic background has largely remained a mystery.

There has been significant effort to uncover the genetic variants causing canine hip dysplasia, but validation and replication of the results have been difficult for a variety of reasons such as inadequate sample size or complex or inaccurate phenotypes, said Jonas Donner, Ph.D., Discovery Manager at Wisdom Health Genetics. For this study, we were able to leverage an extensive sample size, helping partially solve this validation issue and set us on a path for future discoveries related to canine hip dysplasia.

Researchers at University of Helsinki and Wisdom Health Genetics examined genetic samples from a cohort of more than 1600 dogs across ten different breeds. The study validated more than 20 previously-identified genetic regions across 14 chromosomes associated with canine hip dysplasia; while 20 of the loci were associated with specific breeds, one locus was associated across all ten breeds in the study.

According to Lea Mikkola, who conducted this research as part of her PhD dissertation, this study is one of the most extensive pieces of research into the relationship between DNA and hip dysplasia to date.

Overall, these results indicate that canine hip dysplasia has a complex genetic architecture. Many genes contribute, and those genes are different in different breeds, explains Mikkola.

Additional examination of the loci validated in the study will be essential in helping scientists and veterinarians alike understand the genetic pathways contributing to this debilitating condition.

It is critical to look further into these validated loci in the future to find out the actual causal genes and variants, said Professors Antti Iivanainen and Hannes Lohi, leaders of the research at the University of Helsinki, in the Universitys news release about the hip dysplasia study. It is not an easy task but could reveal insights into disease mechanisms and guide towards better care and treatment of this detrimental condition.

The researchers recommend future validation studies to further understand the complex genetic causes of canine hip dysplasia, especially examinations within both specific and disparate breeds, and across various geographical regions. Additional studies to identify causal genetic variants can also help shed light on the molecular causes of the canine hip dysplasia and direct future diagnostic and treatment options.

About the canine hip dysplasia study:

About Wisdom Health GeneticsThe mission of the Wisdom Health business, a division of Kinship Partners, Inc, is to strengthen the bond between pets and their people through world-leading insights powered by DNA. Wisdom Panel dog DNA testsbacked by WISDOM HEALTH scientific researchcan help pet parents plan better, care smarter, and love longer. For more than a decade, Wisdom Health scientific research has contributed to state-of-the-art genetic tests for companion animals, revolutionizing personalized pet care. By unlocking the secrets of their dog or cat's DNA, pet parents and veterinarians can work together to tailor wellness programs that fit the one-of-a-kind needs of their pets. More than 7,000 veterinarians worldwide recommend and offer Wisdom Panel products. For more information, visit http://www.wisdompanel.com, and follow the Wisdom Panel brand on Facebook and Instagram.

About Kinship Partners, IncKinship is here to help everyone pet parent like a pro. Why? Because our pets make us better humans, and we owe them the best possible care. As allies to pet parents learning on the job, we use our data, products, and services to help people be the best pet parents they can be. We unite changemakers in pet care to break down barriers, open new doors, share insights, and advance our collective knowledge. By reimagining the pet parenting experience and upping peoples confidence, were helping the world find better ways to care.

Our coalition includes our world-leading Wisdom Panel genetic health screening and DNA testing for dogs, the award-winning Whistle GPS dog tracker and health monitor, Pet Insight Project, our ground-breaking science stream that uses AI to turn billions of data points into actionable insights, and partnerships like our Leap Venture Studio accelerator that supports innovators and start-ups, to bring new solutions to pet parents. Kinship is a division of Mars Petcare. Learn more at http://www.kinship.co.

About Mars PetcarePart of Mars, Incorporateda family-owned business with more than a century of history-making diverse products and offering services for people and the pets people lovethe 85,000 Associates across 50+ countries in Mars Petcare are dedicated to one purpose: A BETTER WORLD FOR PETS. With 85 years of experience, our portfolio of almost 50 brands serves the health and nutrition needs of the worlds petsincluding brands PEDIGREE, WHISKAS, ROYAL CANIN, NUTRO, GREENIES, SHEBA, CESAR, IAMS, and EUKANUBA, as well as the Waltham Petcare Science Institute, which has advanced research in the nutrition and health of pets for over 50 years. Mars Petcare is also a leading veterinary health provider through an international network of over 2,000 pet hospitals and diagnostic services including BANFIELD, BLUEPEARL, VCA, Linnaeus, AniCura, and Antech. Were also active in innovation and technology for pets, with Wisdom Panel genetic health screening and DNA testing for dogs, the WHISTLE GPS dog tracker, LEAP VENTURE STUDIO accelerator, and COMPANION FUND programs that drive innovation and disruption in the pet care industry. As a family business guided by our principles, we are privileged with the flexibility to fight for what we believe inand we choose to fight for our purpose: A BETTER WORLD FOR PETS.

View original post here:
Genetic Origins of Canine Hip Dysplasia Evaluated in Validation Study - Business Wire

Read More...

Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacte | IDR – Dove Medical Press

February 14th, 2021 7:30 pm

Sosina Ayalew,1,2 Teklu Wegayehu,2 Hawult Taye,1 Liya Wassie,1 Selfu Girma,1 Stefan Berg,3 Adane Mihret1

1Armauer Hansen Research Institute, Addis Ababa, Ethiopia; 2Department of Biology, College of Natural Sciences, Arba Minch University (AMU), Arba Minch, Ethiopia; 3Bacteriology Department, Animal and Plant Health Agency, Weybridge, UK

Correspondence: Sosina Ayalew Tel +251 912166324Email absosina2011@gmail.com

Background: Tuberculosis lymphadenitis (TBLN) is a growing public health concern in Ethiopia. However, there is limited information available on gene mutations conferring drug resistance and genetic diversity of M. tuberculosis isolates from TBLN patients.Methods: Drug resistance and genetic diversity analysis were done on 91 M. tuberculosis isolates from culture positive TBLN patients collected between 2016 and 2017. Detection of mutations conferring resistance was carried out using GenoType MTBDRplus VER 2.0. Thereafter, isolates were typed using spoligotyping.Results: Out of the 91 strains, mutations conferring resistance to rifampicin (RIF) and isoniazid (INH) were observed in two (2.2%) and six (6.6%) isolates, respectively. The two RIF resistant isolates displayed a mutation at codon 531 in the rpoB gene with amino acid change of S531L. Among the six INH resistant strains, four isolates had shown mutation at the KatG gene at codon 315 with amino acid change of S315T, one isolate had a mutation at the inhA gene at codon 15 with amino acid change of C15T and one isolate had a mutation at the inhA gene with unknown amino acid change. All drug resistant isolates were from treatment naive TBLN patients. The dominantly identified Spoligo International Types (SITs) were SIT25, SIT149, and SIT53, respectively; these accounted for 43% of the total number of strains. The isolates were grouped into four main lineages; Lineage 1 (2, 2.2%), Lineage 3 (38, 41.7%), Lineage 4 (49, 53.8%) and Lineage 7 (2, 2.2%). Four out of six (66.7%) isolates with drug resistance conferring mutations belonged to clustered strains (strains with shared SIT).Conclusion: The detection of drug resistant conferring mutation in treatment nave TBLN patients together with detection of drug resistant isolates among clustered strains might suggest resistant strains transmission in the community. This needs to be carefully considered to prevent the spread of drug resistant clones in the country.

Keywords: drug resistant, genetic diversity, mutation, tuberculosis lymphadenitis

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Visit link:
Drug Resistance Conferring Mutation and Genetic Diversity of Mycobacte | IDR - Dove Medical Press

Read More...

Bovine production-medicine expert joins TTU School of Veterinary Medicine Faculty – KLBK | KAMC | EverythingLubbock.com

February 14th, 2021 7:29 pm

AMARILO and LUBBOCK, Texas (NEWS RELEASE) The following is a news release from Texas Tech University:

Community, integrity, kindheartedness, grit, inspiration. These are the values that embody the purpose and vision of theTexas Tech School of Veterinary Medicine in Amarillo. Theyre among the characteristics that make West Texas what it is today.

Those also are values that veterinarian Pedro Melendez shares and holds deeply. As a worldwide expert in beef and dairy cattle production medicine and nutrition, Melendez has spent the last 30 years imparting his wisdom and knowledge to veterinarians and veterinary students around the globe. Now, he will bring that experience, wisdom and knowledge to Texas.

Melendez is the newest faculty member of the Texas Tech School of Veterinary Medicine, joining a diverse collection of experts as an associate professor. He began his duties on Monday (Feb. 8).

I am very excited to begin my academic adventure at Texas Tech, Melendez said. Like any new veterinary school, the challenge is huge, but at the same time rewarding, because it will give me the opportunity to leave a legacy that can be remembered forever. In this sense, I am committed to thoroughly following the core values of Texas Tech, not because it is an obligation but because it is my lifestyle. These are the values that I inherited from my parents, and I will put them into practice day by day with the students, my colleagues, the staff and the entire community with which I will live.

Melendez comes to Texas Tech after spending the last three years as a clinical associate professor at the University of Georgia where he taught courses in population health, discussing published veterinary research and new research developments as well as management approaches and current issues in the diagnosis of disease and health maintenance on domestic and wild animal populations.

While at Georgia he also served in a graduate appointment in animal and dairy sciences at the universitys College of Veterinary Medicine as well as a graduate appointment in animal sciences at Colorado State University.

Prior to his time in Georgia, Melendez served on the faculty at the University of Missouri in Columbia, focusing on dairy production and food animal medicine. Dairy production medicine and cattle nutrition have also been his focus in teaching stops at the University of Florida and the University Santo Tomas in Chile.

I hope I can bring new ideas to Texas Tech that can help me interact positively with everybody, because I have a gregarious personality, Melendez said, Teamwork is my slogan, and I am sure it is the spirit of all at Texas Tech.

His goal at Texas Tech is to connect with the practitioners as well as owners and managers of local dairies to help teach students and collaborate on applied research. Melendez also hopes to establish a service laboratory for the diagnosis of metabolic diseases, metabolic profiling and nutritional monitoring to support the labor of bovine practitioners and nutritionists.

An important component of our mission is to support the sustainability our nations livestock industries, saidGuy Loneragan, dean of the School of Veterinary Medicine. Animal agriculture has been at the heart of Texas since its inception. The two are interwoven in the fabric of what and who we are. Animal agriculture helps drive the states economy, and the School of Veterinary Medicine is located at the epicenter of this industry. The insights and expertise Dr. Melendez brings adds to the vibrancy of our school and the region. He also brings a worldview that makes us all better.

Melendez is a member of the American Board of Veterinary Medicine, the American Veterinary Medical Association, the American Association of Bovine Practitioners and the American Dairy Science Association.

He earned his bachelors degree in veterinary science and his Doctor of Veterinary Medicine from the University of Chile, and his masters and doctoral degrees in veterinary science from the University of Florida. He also served his residency in food animal reproduction and medicine from Florida. He earned his board certification in dairy practice from the American Board of Veterinary Practitioners in 2019 and served seven years in general bovine medical practice upon earning his veterinary degree in 1990.

Dr. Melendez brings a national and international background in dairy production medicine to our school, saidJohn Dascanio, senior associate dean for academic and student affairs. He has years of experience and a passion to help the dairy industry. He is not only committed to helping the region but also will incorporate international continuing education and engagement. I look forward to his work with our dairy community, with it being one of the largest milksheds in the country.

Thanks to the generosity of Amarillo and communities across Texas, and the commitment of legislators from around the state, the Texas Tech University School of Veterinary Medicine in Amarillo was established in 2018. In September 2020, the school was granted a Letter of Reasonable Assurance, from the American Veterinary Medical Association (AVMA) Council on Education and has begun the admissions process in preparation for classes to begin in August.

The School of Veterinary Medicine will recruit and select students with a passion to serve rural and regional communities. Its curriculum is focused on the competencies and skills necessary for success in practice types that support these communities. Texas Techs innovative and cost-efficient model partners with the wider community of veterinary practices across the state to provide clinical, real-world experiential learning.

(News release from Texas Tech University)

Continued here:
Bovine production-medicine expert joins TTU School of Veterinary Medicine Faculty - KLBK | KAMC | EverythingLubbock.com

Read More...

New Veterinary Hospital Gets New Name Thanks to Generosity of PVM Alumnus and His Wife – Purdue Veterinary News

February 14th, 2021 7:29 pm

Friday, February 12, 2021

As the date for opening the Purdue University College of Veterinary Medicines new hospital facilities draws closer, the Purdue Board of Trustees has approved a new name for the complex in recognition of a $10 million leadership commitment from PVM alumnus David Brunner and his wife, Bonnie. The board took the action at its meeting Friday, February 5, honoring the Brunners for their gift that will be meaningful to students, staff, faculty, clients, and alumni alike for years ahead.

Encompassing 162,500 square feet, the new veterinary hospital facilities will be known as the David and Bonnie Brunner Purdue Veterinary Medical Hospital Complex, and will include three components located just east of the existing Lynn Hall of Veterinary Medicine:

As the pandemic has underscored, a state-of-the-art veterinary medicine program now not only benefits our animal population, but is an integral element in protecting human health, said Purdue President Mitch Daniels. Thanks to David and Bonnie, Indiana and the nation will now have such an invaluable asset.

Dr. Brunner earned his Doctor of Veterinary Medicine degree at Purdue in 1979, and then began his career as a practitioner in what he calls the most enjoyable profession in the world. I go to work and play with puppies and kittens. He credits his time as a student at Purdue for fueling his passion.

Dr. Brunner is the owner of the Broad Ripple Animal Clinic (BRAC), a business he founded on the north side of Indianapolis in 1981 with one employee. BRAC now has nine full-time veterinarians and is one of the 15% of hospitals in the U.S. accredited by the American Animal Hospital Association. Dr. Brunner retired as a practicing clinical veterinarian in 2012 but continues to be involved with the clinic as chief visionary and staff cheerleader.

Dr. Brunner has been a member of the Indiana Veterinary Medical Association, the American Veterinary Medical Association, and the American Animal Hospital Association. He is a past president of the Indianapolis Humane Society, having previously served on the board for ten years. In addition, Dr. Brunner has authored two books, The Dog Owners Manual and The Cat Owners Manual, currently published in 12 languages worldwide.

Bonnie (MacLeod) Brunner holds degrees in economics and comparative politics and an MBA in finance from UCLA. She retired from trading at Morgan Stanley and owns Lupo Design & Build, a luxury contemporary residential home building company in Hermosa Beach, Calif. She balances this business with her role as chief financial officer of the veterinary practice and managing the couples personal and commercial properties. Bonnie was actively involved in animal rescue organizations in Los Angeles before meeting David. The Brunners split their time between Indianapolis; Southern California; and St. Barths, French West Indies.

My years at Purdue were life-changing, Dr. Brunner said. It took me a while to appreciate the incredible education I received from Purdues vet school. To this day, I reflect with sincere appreciation on the many professors and clinical instructors who helped shape me into the veterinarian I became.

Bonnie and I have been presented with an extraordinary opportunity to contribute to the construction of the new veterinary medical complex. It is our hope that this contribution will aid and inspire veterinary students, now and for years to come. I am passionate about companion animal practice and have a special interest in inspiring the entrepreneurial spirit in veterinary students and teaching them the art of veterinary practice and the business of veterinary medicine.

The couple is looking forward to having an active role in the Purdue Alumni Association and to finally attending some Boilermaker football games, as they joke, We did not have time to do things like that when we were in school because we were always studying.

The design of the new David and Bonnie Brunner Purdue Veterinary Medical Hospital Complex optimizes hands-on learning for students and creates dedicated space for community engagement opportunities. In addition, the complexs larger footprint and updated equipment will increase clinical research and allow faculty researchers to respond to more clinical trial opportunities, thus expanding the College of Veterinary Medicines reputation as a world-renowned research institute.

Due to the generosity of David and Bonnie Brunner, our vision of constructing a true state-of-the-art hospital is becoming a reality, said Purdue Veterinary Medicine Dean Willie Reed. The new hospital will provide a wonderful learning environment for our students, enable our faculty to advance their clinical research programs that involve clinical trials and greatly enhance our capability to deliver the highest quality care to our animal patients. I am especially grateful to have an alumnus of the college and his wife make such an impactful contribution to the colleges future success.

Slated to be completed by December and open by spring 2022, the new complex will provide for the varied needs of clients while also maximizing efficiency. For the first time, horses will have their own equine hospital rather than being treated at the same facility as farm animals like cows, pigs, and sheep, which will be attended to at the new farm animal hospital. Efficiencies in the existing hospital facility also will be incorporated into the new structures. For example, expensive imaging technology will be located centrally so it can be accessed from both the small animal and equine hospitals, which mirrors current practice in the existing facilities.

Some small animal services will remain at the current small animal hospital. In addition to treating animals, the hospital complex will serve as a catalyst for interdisciplinary research, including cancer drug discovery and the development of treatments for paralysis.

The total cost of the project is $108 million. Purdue has committed $35 million, which includes ongoing fundraising by the College of Veterinary Medicine, and the state of Indiana approved a $73 million appropriation.

Writer(s): Purdue News Service and Kevin Doerr | pvmnews@purdue.edu

Go here to read the rest:
New Veterinary Hospital Gets New Name Thanks to Generosity of PVM Alumnus and His Wife - Purdue Veterinary News

Read More...

Page 192«..1020..191192193194..200210..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick